BSI-730, a first-in-class HER2xPD-L1 bi-specific ADC, demonstrates potent anti-tumor activity in HER2-low models via selective tumor cell killing and immune modulation

Enhertu (fam-trastuzumab deruxtecan-nxki) - Daiichi Sankyo, AstraZeneca

BSI-730 - Biosion

Herceptin (trastuzumab) - Roche

Hui-Han Hu1; Xiaoyao Hao1; Yue Gao1; Hongyan Li1; Jinyu Liu1; Jinge Zhao1; Yi Lu1; Liezhou Ji1; Zhigang Ma1; Mingjiu Chen1; Kedan Lin2

Mar 18, 2026